Pipeline Dawah Pharmaceuticals Inc. is advancing global healthcare through a robust pipeline of essential drugs in collaboration with top-tier international Contract Manufacturing Organizations (CMOs). By leveraging strategic overseas partnerships, we ensure the efficient delivery of FDA-compliant drugs that address critical therapeutic needs across a wide range of disease states. Read More Sterile Injectables Antipsychotics Help manage both chronic and acute mental health disorders to stabilize patients Paralytics Used to facilitate anesthesia and ensure patient immobilization during surgery or critical care Antibiotics Target and treat severe bacterial infections, including resistant strains Oncology Drugs Provide innovative and life-saving treatments for various types of cancer Antifungals Treat systemic and invasive fungal infections effectively. Ophthalmics Anti-inflammatory Agents: Reducing inflammation in ocular diseases. Antibiotic-Corticosteroid Combinations: Treating bacterial infections with concurrent inflammation. Antihistamines: Providing relief from allergic conjunctivitis and related ocular allergies. Bags and (TPN) Pain Management: Offering intravenous acetaminophen for effective pain and fever control. Critical Care Solutions: Including dopamine and electrolytes for emergency and intensive care applications. Nutritional Support: High-use TPN formulations for patients with impaired oral intake. Overseas Partnerships Dawah Pharmaceuticals has meticulously evaluated over 30 global CMOs and strategically partnered with two industry leaders based overseas. These partnerships are integral to our operations Optimize manufacturing costs with contributions of the sterile production cost by our selected CMOs. Activities Provided by CMOs Comprehensive Development: Formulation, process design, and analytical testing. Regulatory Preparedness: Manufacturing registration batches and compiling FDA dossiers. Stability Testing: Ensuring efficacy and safety over extended periods. Our partnerships empower Dawah Pharmaceuticals to maintain agility while delivering high-quality, FDA-compliant drugs to address critical healthcare needs. By continuously assessing market trends and patient requirements, we are committed to expanding our pipeline and improving global access to essential medications. Commitment to Excellence Here is a list of the drugs we plan to bring to the U.S. market via JV, along with their indications and projected launch years. 2026–2027 Bacterial infections (oral antibiotic) 2028 Type 2 diabetes, weight management 2028–2029 Acute heart failure, cardiac stress testing 2028–2029 Edema, congestive heart failure, hypertension 2028–2029 Short-term pain relief (injectable NSAID) 2028–2029 Gallstone dissolution, primary biliary cholangitis 2027–2028 Antiplatelet (cardiovascular diseases) 2028–2029 Sedation in intensive care and surgical settings 2028–2029 Induction of general anesthesia 2028–2029 Short-term pain relief (injectable NSAID) 2028–2029 Alzheimer’s disease 2031 Chemotherapy, autoimmune diseases (oncology)

We deliver care that connects communities to a healthier future. Dawah Pharmaceuticals is redefining access to essential medicine through a global platform built on science, trust, and collaboration. With a presence in the U.S., Egypt, and across the MENA region, our commitment goes beyond manufacturing "Filling the Gap" Dawah Pharmaceuticals is committed to addressing critical shortages in sterile injectable medications by bringing essential, FDA-compliant drugs to market. Through strategic partnerships with top-tier Contract Manufacturing Organizations (CMOs), we ensure a timely response to the healthcare industry's pressing needs. "Innovative Outsourcing Models" Leveraging our partnerships with global CMOs, Dawah Pharmaceuticals focuses on efficient, high-quality drug production without the constraints of traditional manufacturing. This approach allows us to accelerate timelines and maintain flexibility, ensuring that critical medications reach patients faster. "Strategic Growth and Market Entry" Our portfolio includes high-priority products produced exclusively through CMOs. By prioritizing collaboration and scalability, Dawah is building a sustainable framework to expand its market presence and deliver impactful solutions across multiple therapeutic areas. "Injectable and ophthalmic pharmaceutical company" We market and manufacture a growing portfolio of FDA-approved medicines, including several generic alternatives, in the United States. Our products include both injectable and ophthalmic prescription medicines. Explore Our Products Trusted pharmaceutical solutions designed with science View More ABOUT DAWAH Dawah Pharmaceuticals is a U.S.-based pharmaceutical company with a global vision and deep regional roots. Backed by over 30 years of leadership experience in healthcare, Dawah bridges U.S. regulatory expertise with Egyptian manufacturing excellence to deliver quality medicines worldwide. Through its strategic joint ventures Dawah-Gypto Pharma and Dawah-Holdi Pharma the company operates internationally accredited facilities producing over 200 million units annually. Dawah’s diverse portfolio spans sterile injectables, oral medications, and wellness products, all aligned with the highest global standards. Headquartered in the United States with an expanding footprint across Egypt and the MENA region, Dawah Pharma is committed to advancing quality, affordability, and access to care across continents. Our Team Contact Us Submit

Strategic Partnership Signed Between Dawah Pharma LLC (USA) and Bateel Group Holding A strategic partnership agreement has been signed in Cairo between Dawah Pharma LLC (USA) and Bateel Group Holding, in the presence of key industry and government representatives. The agreement aims to upgrade pharmaceutical production lines in compliance with FDA standards and introduce new investments to support the export of Egyptian pharmaceuticals to global markets. This milestone builds on Dawah Pharma’s successful collaborations in Egypt with Gypto Pharma City and Dawah Holdi, reinforcing its commitment to enhancing the competitiveness of the Egyptian pharmaceutical industry, transferring global technologies, and strengthening Egypt’s position as a leading regional hub for pharmaceutical manufacturing and export

Dr. Hossam Abdel Maqsoud Hosts Diplomatic Dinner Celebrating the Appointment of Ambassador Mohamed El-Helwany as Egypt’s Ambassador to Guinea Dr. Hossam Abdel Maqsoud, Chairman of Dawah Pharma USA and Board Member of the Egyptian African Businessmen Association, hosted a dinner at the Diplomatic Club in honor of the appointment of Ambassador Mohamed El-Helwany as Egypt’s Ambassador to the Republic of Guinea The event was attended by distinguished figures from the diplomatic, economic, and media sectors, including: Dr. Abdelhakim El Waer, Assistant Director-General and Regional Representative for the Near East and North Africa – FAO H.E. Sim Monir Cisse, Ambassador of Guinea to Egypt Dr. Yousry El Sharkawy, President of the Egyptian African Businessmen Association Eng. Ahmed Al Assar, Chairman of Massar Mr. Magdy Mounir, Editor-in-Chief at Al-Ahram Dr. Wael Youssef, CEO of Al Nasr Export & Import Mr. Willy Dowlaty, Vice Chairman of Taamir Mr. Ahmed Yassin, Vice Chairman of Dawah Pharma Mr. Karim Ismail, Chairman of Scope Sports and Board Member of the Association Eng. Ahmed Samir, Board Member of the Association During the event, Dr. Abdel Maqsoud highlighted the company’s strong growth strategy across Africa, aiming to expand the presence of high-quality Egyptian pharmaceuticals into new markets—both across the African continent and from Egypt into the United States He also emphasized that Dawah Pharma is actively working towards securing U.S. FDA approval to reinforce global trust in Egyptian medical products and strengthen Egypt’s position as a key player in the international pharmaceutical industry

We’re here to support your health and your business Contact Information Our Locations : Dawah Holdi Company 26 Galal El-Din El-Desouky Street – 1st Floor – Apartment 3 – Almaza – Cairo Dawah Gypto Company Plot 27 – Industrial Zone – Khanka – Abu Zaabal – Qalyubia Governorate2nd Floor – Inside the premises of Gypto Company New York 125 Michael Drive, Suite 106 Syosset, NY 11719 Get in Touch with Our Team : 01200060637 Email: info@dawahpharma.com +1 347 669 1693 Social Media: Submit

GYPTO Pharma Signs Preliminary Agreement with Mozambique Government to Establish Regional Pharmaceutical Distribution Hub Dawah Gypto has signed a preliminary agreement with the Government of Mozambique to establish a regional pharmaceutical distribution hub and a packaging facility for liquid and semi-liquid medications This strategic step reinforces the company’s presence in the Southern African region, enhancing access to high-quality and affordable medicines within SADC countries. The collaboration reflects strong confidence in Dawah Gypto’s capabilities and its commitment to supporting sustainable healthcare development. The project will contribute to improving medicine availability, creating local job opportunities, and advancing technology transfer in the pharmaceutical sector. Dawah Gypto continues to expand its footprint across Africa with a clear vision to elevate healthcare standards and deliver life-saving treatments to communities across the continent.

Egypt Signs Strategic Tripartite Partnership to Build an Integrated Medical Manufacturing Ecosystem for Regional & Global Markets Read More Strategic Partnership Signed Between Dawah Pharma LLC (USA) and Bateel Group Holding Read More Dr. Hossam Abdel Maqsoud Hosts Diplomatic Dinner Celebrating the Appointment of Ambassador Mohamed El-Helwany as Egypt’s Ambassador to Guinea Read More GYPTO Pharma Signs Preliminary Agreement with Mozambique Government to Establish Regional Pharmaceutical Distribution Hub Read More Egypt’s Gypto Pharma (Medicine City) and US-based Dawa Pharmaceuticals signed a strategic alliance agreement aimed at strengthening Egypt’s pharmaceutical industry and achieving US Food and Drug Administration (FDA) qualification for Gypto Pharma’s facilities Read More

توماس إنغالينيرا نائب الرئيس للعمليات يشغل الدكتور توماس إنغالينيرا منصب نائب الرئيس للعمليات، ويملك أكثر من 40 عامًا من الخبرة في البحث والتطوير الدوائي، مع تخصص في أشكال الجرعات القابلة للحقن. يقدم الدكتور إنغالينيرا القيادة التقنية والعلمية عبر برامج تطوير الأدوية، داعمًا المشاريع منذ مرحلة ما قبل التكوين وحتى الإنتاج التجاري الكامل. وقد شغل مناصب عليا في مؤسسات عالمية رائدة، بما في ذلك Pharmaceutics International، وBioCryst Pharmaceuticals، وParenta Pharmaceuticals، وAAI Pharma، وGenzyme، وBurroughs Wellcome، وA.H. Robins. يحمل شهادة بكالوريوس العلوم في الصيدلة ودكتوراه في الصيدلة من جامعة فيرجينيا كومنولث. وبالإضافة إلى دوره التنفيذي، يعمل الدكتور إنغالينيرا عضوًا في مجموعة الاستشارات التقنية لمؤسسة بيل وميليندا غيتس، مساهماً بخبراته في المبادرات الصحية العالمية.

Amany El Megharbel Vice President of Finance and Banking Strategy Amany El Megharbel brings more than 29 years of experience in banking and financial services, with deep expertise in private banking, asset management, and digital banking solutions. She previously served as Head of Branches, Financial Institutions, and Asset Management at Banque Misr UAE, where she played a key role in improving operational efficiency and profitability. Prior to that, she led the launch of BLOM Bank Egypt’s Private Banking division and drove innovative banking initiatives at Credit Agricole and Egyptian American Bank. Amany holds certifications in Wealth Management and Financial Planning and Asset Allocation, along with a Bachelor's degree in Commercial Sciences. Her extensive experience and financial leadership play a strategic role in supporting Dawah Pharma’s growth and long-term vision.

Mohamed AlNadi Vice President, International Expansion and Partnerships (MENA and Africa) Dr. Mohamed Alnadi serves as the Vice President of International Expansion and Partnerships for the MENA and Africa regions. With over 25 years of experience in international trade, export operations, and strategic market growth, he has successfully expanded business footprints across more than 60 countries. Since 2002, Dr. Alnadi has led Alnadi Pharmacy Company, establishing it as a trusted name in the pharmaceutical and healthcare sectors. He previously held the position of Managing Director at EgyBelg for Industrial Investment, where he specialized in biotechnology and enzyme production. He also managed a leading food manufacturing company, driving its expansion across regional and global markets. Dr. Alnadi holds a Bachelor’s degree in Pharmacy from Cairo University and a Business Administration Diploma from the American University in Cairo.

Dr. Hossam Abdel Maksoud Chief Executive Officer Nicholas Vartanian Corporate Development, Founder Mohamed AlNadi Vice President, International Expansion and Partnerships (MENA and Africa) Thomas Ingallinera Vice President of Operations Mathew Cherian Chief Operating Officer and Co-Founder Amany El Megharbel International Investment Advisor Dr. Helmy Nada Fund Manager, Dawah Holdings

Mathew Cherian Chief Operating Officer and Co-Founder Mathew Cherian is the Chief Operating Officer and Co-Founder of the company, bringing more than 34 years of international experience in the pharmaceutical industry across the United States and Europe. Before co-founding the organization, Mr. Cherian served as Director and Senior Fellow at a leading global pharmaceutical company. During his tenure, he played a key role in early stage product development and successfully coordinated research efforts across multiple global Pfizer sites. His extensive expertise in complex pharmaceutical products continues to support the development of innovative therapies across several therapeutic areas. Mr. Cherian is a recognized expert in drug device combination products and is a leader in advancing differentiated drug delivery systems, contributing to the development of high-value, advanced pharmaceutical solutions. He holds a Ph.D. in Chemical Engineering from the University of Rhode Island and is an inventor with multiple patents. Widely regarded as a thought leader in the industry, he regularly speaks at global pharmaceutical forums and serves on the Executive Committee of the International Pharmaceutical Society. enhance community well being.